Grant Of Options

RNS Number : 9167A
MaxCyte, Inc.
24 January 2020





MaxCyte, Inc.

("MaxCyte" or the "Company")


Grant of Options


Gaithersburg, Maryland - 24 January 2020: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life sciences company, announces that on 20 January 2020, a total of 729,200 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). The annual 2020 grants were approved at a Board Meeting in December 2019, subject to issuance being following announcement of the Company's recent trading update ("Trading Update").  Details of the Option Grants are given below:


Option Grants to PDMRs

Doerfler, Doug


Holtz, Ron


Thompson, J. Stark


Mandell, Art


Erck, Stan


Brooke, Will


Johnston, John


Douglas, Richard





Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 20 January 2020, of 136.00 pence (being the closing share price on the day of the Trading Update).


The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:



Details of the person discharging managerial responsibilities / person closely associated 



Doerfler, Doug

Holtz, Ron

Thompson, J. Stark

Mandell, Art

Erck, Stan

Brooke, Will

Johnston, John

Douglas, Richard


Reason for the notification




Doerfler, Doug - CEO and Director

Holtz, Ron - CFO and Director

Thompson, J. Stark - Non-executive Chairman

Mandell, Art - Non-executive Director

Erck, Stan - Non-executive Director

Brooke, Will - Non-executive Director

Johnston, John - Non-executive Director

Douglas, Richard - Non-executive Director


Initial notification /Amendment 

Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 



MaxCyte, Inc.






Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted



Description of the financial instrument, type of instrument

Grant of Options over Shares of Common Stock


Identification code  



Nature of the transactions  


Grant of Options to PDMRs



Price(s) and volume(s)

Doerfler, Doug - 390,200 at an exercise price of 136.00  pence

Holtz, Ron - 177,600 at an exercise price of 136.00  pence

Thompson, J. Stark - 26,900 at an exercise price of 136.00 pence

Mandell, Art - 26,900 at an exercise price of 136.00  pence

Erck, Stan - 26,900 at an exercise price of 136.00  pence

Brooke, Will - 26,900 at an exercise price of 136.00  pence

Johnston, John - 26,900 at an exercise price of 136.00  pence

Douglas, Richard - 26,900 at an exercise price of 136.00  pence



Aggregated information 

- Aggregated volume

- Price




Date of the transactions 

20 January 2020


Place of the transaction

Outside a trading venue



About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 100 partnered programme licenses in cell therapy with more than 70 licensed for clinical use. The Company has now signed eight clinical/commercial licenses with leading cell therapy developers and the potential pre-commercial milestones from these relationships now exceeds $650 million.  With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. MaxCyte is also developing novel CARMA therapies, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. MaxCyte has established CARMA as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform. For more information, visit


For further information, please contact:


MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer



+1 301 944 1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns



+44 (0)20 7886 2500


Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith



+44 (0)20 7260 1000

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji





+44 (0)203 709 5700


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
UK 100

Latest directors dealings